Revvity Q3 2026: Earnings Beat and a Raised Full-Year Outlook
As seen on the 24/7 Wall St. homepage on November 3, 2026.
Revvity raised its full-year outlook to pro forma adjusted EPS of $5.40 to $5.45 after beating expectations on both lines. An Investor Day on November 13 adds detail on the turnaround.
Continue ReadingShow less
Revvity beat expectations on both lines in the third quarter of fiscal 2026, its eighth straight quarter of topping EPS estimates.
Life Sciences drove the result, with adjusted operating margin expanding to 31.5%, and Diagnostics margin improved as well.
Sponsored
Management raised full-year 2026 pro forma guidance to roughly 5% organic growth, excluding the China Immunodiagnostics business it is divesting.
The November 13 Investor Day is the next concrete catalyst for gauging the durability of the turnaround.
Mentioned: RVTY